Nasdaq:US$13.41 (-0.23) | HKEX:HK$21.15 (+0.00) | AIM:£2.22 (+0.02)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors